Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
October 10 2023 - 7:25AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2023
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
99.1
|
10
October 2023 - “Holding(s) in Company”
|
99.1
10 October 2023
HALEON PLC
("Haleon" or "the
Company")
TR-1: Standard form for notification of major
holdings
1. Issuer Details
ISIN
Issuer Name
UK or Non-UK Issuer
2. Reason for Notification
|
An acquisition or disposal of voting rights
|
3. Details of person subject to the notification
obligation
Name
City of registered office (if applicable)
Country of registered office (if applicable)
|
Name
|
City
of registered office
|
Country
of registered office
|
|
GSK GP
1 Limited
|
Edinburgh
|
Scotland
|
|
GSK LP
Limited
|
London
|
England
|
4. Details of the shareholder
|
Name
|
City
of registered office
|
Country
of registered office
|
|
Vidacos
Nominees Limited
|
London
|
England
|
5. Date on which the threshold was crossed or reached
6. Date on which Issuer notified
7. Total positions of person(s) subject to the notification
obligation
|
|
% of voting rights attached to shares (total of 8.A)
|
% of voting rights through financial instruments (total of 8.B 1 +
8.B 2)
|
Total of both in % (8.A + 8.B)
|
Total number of voting rights held in issuer
|
|
Resulting
situation on the date on which threshold was crossed or
reached
|
7.420000
|
0.000000
|
7.420000
|
685320110
|
|
Position
of previous notification (if applicable)
|
10.350000
|
0.000000
|
10.350000
|
|
8. Notified details of the resulting situation on the date on which
the threshold was crossed or reached
8A. Voting rights attached to shares
|
Class/Type of shares ISIN code(if possible)
|
Number of direct voting rights (DTR5.1)
|
Number of indirect voting rights (DTR5.2.1)
|
% of direct voting rights (DTR5.1)
|
% of indirect voting rights (DTR5.2.1)
|
|
GB00BMX86B70
|
0
|
685320110
|
0.000000
|
7.420000
|
|
Sub
Total 8.A
|
685320110
|
7.420000%
|
8B1. Financial Instruments according to (DTR5.3.1R.(1)
(a))
|
Type of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Number of voting rights that may be acquired if the instrument is
exercised/converted
|
% of voting rights
|
|
|
|
|
|
|
|
Sub
Total 8.B1
|
|
|
|
8B2. Financial Instruments with similar economic effect according
to (DTR5.3.1R.(1) (b))
|
Type of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Physical or cash settlement
|
Number of voting rights
|
% of voting rights
|
|
|
|
|
|
|
|
|
Sub
Total 8.B2
|
|
|
|
9. Information in relation to the person subject to the
notification obligation
|
2. Full chain of controlled undertakings through which the voting
rights and/or the financial instruments are effectively held
starting with the ultimate controlling natural person or legal
entities (please add additional rows as necessary)
|
|
Ultimate controlling person
|
Name of controlled undertaking
|
% of voting rights if it equals or is higher than the notifiable
threshold
|
% of voting rights through financial instruments if it equals or is
higher than the notifiable threshold
|
Total of both if it equals or is higher than the notifiable
threshold
|
|
GSK plc
(Chain 1)
|
|
2.850000
|
|
2.850000%
|
|
GSK plc
(Chain 1)
|
GlaxoSmithKline
Holdings Limited (Chain 1)
|
2.850000
|
|
2.850000%
|
|
GSK plc
(Chain 1)
|
GlaxoSmithKline
Finance plc (Chain 1)
|
2.850000
|
|
2.850000%
|
|
GSK plc
(Chain 1)
|
Glaxo
Group Limited (Chain 1)
|
2.850000
|
|
2.850000%
|
|
GSK plc
(Chain 2)
|
|
4.580000
|
|
4.580000%
|
|
GSK plc
(Chain 2)
|
GSK LP
Limited (Chain 2)
|
4.580000
|
|
4.580000%
|
|
GSK plc
(Chain 2)
|
GSK GP
1 Limited (Chain 2)
|
4.580000
|
|
4.580000%
|
|
GSK plc
(Chain 2)
|
GSK
(No. 1) Scottish Limited Partnership (Chain 2)
|
4.580000
|
|
4.580000%
|
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
|
GSK plc is making this notification on behalf of itself and on
behalf of GSK LP Limited and GSK GP 1 Limited.This notification
relates to the sale by GSK (No.1) Scottish Limited Partnership, GSK
(No.2) Scottish Limited Partnership and GSK (No.3) Scottish Limited
Partnership (entities that are indirectly wholly-owned by GSK plc)
of (in the case of GSK (No.1) Scottish Limited Partnership) a
portion of its interest and (in the case of GSK (No.2) Scottish
Limited Partnership and GSK (No.3) Scottish Limited Partnership)
all of their respective interests in Haleon plc.GSK GP 1 Limited is
the sole general partner of GSK (No.1) Scottish Limited Partnership
and GSK (No.2) Scottish Limited Partnership. GSK LP Limited is the
sole limited partner of GSK (No.1) Scottish Limited Partnership,
GSK (No.2) Scottish Limited Partnership and GSK (No.3) Scottish
Limited Partnership.Glaxo Group Limited and GSK (No.1) Scottish
Limited Partnership hold their shares in Haleon plc via a
custodian, Vidacos Nominees Limited, which holds the legal title to
those shares on their behalf pursuant to a custody
arrangement.
|
12. Date of Completion
13. Place Of Completion
Amanda Mellor, Company Secretary
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
Date:
October 10, 2023
|
By:
|
/s/
Amanda Mellor
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|
Haleon (NYSE:HLN)
Historical Stock Chart
From Dec 2024 to Jan 2025
Haleon (NYSE:HLN)
Historical Stock Chart
From Jan 2024 to Jan 2025
